RICHMOND, Va., Nov. 4, 2014 /PRNewswire/ — Reckitt Benckiser Pharmaceuticals Inc., a global specialty pharmaceutical company committed to pioneering innovative and accessible therapies for the chronic diseases of addiction and related mental health disorders, today announced the appointment of Cary J. Claiborne as Chief Financial Officer. Cary will lead the company’s global financial and information technology operations, reporting to Chief Executive Officer Shaun Thaxter effective November 10, 2014.
Cary was selected based on his unique combination of operational and pharmaceutical experience, which is expected to help drive value creation for shareholders. Prior to his appointment at Reckitt Benckiser Pharmaceuticals, Cary served as Chief Financial Officer of Sucampo Pharmaceuticals Inc., where he led the company’s worldwide finance, human resources, information technology, investor relations and communications organizations. Previously, Cary held senior positions at New Generation Biofuels, Osiris Therapeutics, Constellation Energy, Home Depot Corporation, MCI and General Electric. He graduated from Rutgers University with a BA in Business Administration and earned his MBA in Finance from Villanova University.
About Reckitt Benckiser Pharmaceuticals Inc.
Reckitt Benckiser Pharmaceuticals Inc. is a specialty pharmaceutical company with decades of heritage in serving the opioid dependence treatment community. Committed to expanding education and access to medical therapies, the company innovates, manufactures and markets medications that, in conjunction with counseling and psychosocial support, treat opioid dependence. Reckitt Benckiser Pharmaceuticals continues to invest resources in raising awareness of the chronic disease within the community, while also sponsoring training programs for physicians to become certified to treat opioid dependent patients.
Reckitt Benckiser Pharmaceuticals is a wholly owned subsidiary of Reckitt Benckiser Group plc (RB), a global company publicly traded on the UK stock exchange. On July 25, 2014 the RB Board concluded that a demerger of the Reckitt Benckiser Pharmaceuticals business is the preferred option for creating value for shareholders. RB expects to be in a position to demerge the business prior to December 31, 2014 following approval of RB shareholders. At that time, Reckitt Benckiser Pharmaceuticals will operate independently under the separate holding company Indivior PLC, which will be listed on the London Stock Exchange. The name Indivior was selected as it aptly embodies Reckitt Benckiser Pharmaceuticals’ vision, mission and values dedicated to transforming addiction from a global human crisis to an actively treated chronic disease. Indivior is the fusion of the words individual and endeavor.